Literature DB >> 27704534

The Longitudinal Course of Pain and Analgesic Therapy Following Aneurysmal Subarachnoid Hemorrhage: A Cohort Study.

Athir H Morad1, Rafael J Tamargo2, Allan Gottschalk1,2.   

Abstract

OBJECTIVE: The purpose of this study was to determine the duration, intensity, location, and usual treatment of pain throughout hospitalization following subarachnoid hemorrhage.
BACKGROUND: Headache following subarachnoid hemorrhage can be sudden and severe. Little is known about the longitudinal course of headache or its analgesic therapy following the initial diagnosis of subarachnoid hemorrhage.
METHODS: A prospectively maintained database of 564 patients diagnosed with cerebral aneurysms collected from 10/2009 to 2/2013 was searched for conscious patients with subarachnoid hemorrhage. Available electronic records were queried for pain scores (0-10/10), location, and analgesic consumption.
RESULTS: Forty-six adults with subarachnoid hemorrhage met eligibility criteria for inclusion. Mean [CI 95] daily pain was 3.8 [3.2, 4.4] and maximal daily pain was 5.8 [5.1, 6.6]. Eighty-nine percent of patients reported severe pain of 7-10/10, and 63% of patients reported 10/10 pain at some point during hospitalization. While mean [CI 95] pain declined over the course of hospital stay at a rate of 0.06 [0.04, 0.07] units/day (P < .001), mean [CI 95] maximal daily pain changed at a rate of -0.03 [-0.06, 0.01] units/day, which is not significantly different than zero (P = .15). Pain was located primarily in the head in 76% of subjects but pain in the back, neck, limbs, and eyes was also reported. All patients received oral acetaminophen with increasing daily doses. All but three patients, received opioids, most commonly intravenous fentanyl and oral oxycodone. The mean [95 CI] intravenous morphine equivalent dose of opioids consumed was 15.7 [10.3, 21.1] mg/day and changed at a rate of -0.11 [-0.37, 0.15] mg/day which is not significantly different than zero (P = .40).
CONCLUSION: Despite steady consumption of analgesics, the pain reported by conscious patients while recovering from subarachnoid hemorrhage in the hospital is often severe and persists throughout hospitalization.
© 2016 American Headache Society.

Entities:  

Keywords:  acute pain; analgesic therapy; headache; subarachnoid hemorrhage

Mesh:

Substances:

Year:  2016        PMID: 27704534     DOI: 10.1111/head.12908

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  5 in total

1.  Pain Control and Anxiolysis After Subarachnoid Hemorrhage Using Immersive Virtual Reality: A Case Report.

Authors:  Adam Kardon; Robert S Murray; Mazhar Khalid; Luana Colloca; J Marc Simard; Neeraj Badjatia; Sarah B Murthi; Nicholas A Morris
Journal:  Neurohospitalist       Date:  2022-05-12

2.  Acute Headache Management for Patients with Subarachnoid Hemorrhage: An International Survey of Health Care Providers.

Authors:  Carolina B Maciel; Brooke Barlow; Brandon Lucke-Wold; Arravintha Gobinathan; Zaid Abu-Mowis; Mounika Mukherjee Peethala; Lisa H Merck; Raffaele Aspide; Katie Dickinson; Guanhong Miao; Guogen Shan; Federico Bilotta; Nicholas A Morris; Giuseppe Citerio; Katharina M Busl
Journal:  Neurocrit Care       Date:  2022-08-02       Impact factor: 3.532

3.  Severe headache trajectory following aneurysmal subarachnoid hemorrhage: the association with lower sodium levels.

Authors:  Robert S Eisinger; Zachary A Sorrentino; Brandon Lucke-Wold; Sonya Zhou; Brooke Barlow; Brian Hoh; Carolina B Maciel; Katharina M Busl
Journal:  Brain Inj       Date:  2022-03-30       Impact factor: 2.167

4.  Pharmaceutical Management for Subarachnoid Hemorrhage.

Authors:  Arnav Barpujari; Chhaya Patel; Rebecca Zelmonovich; Alec Clark; Devan Patel; Kevin Pierre; Kyle Scott; Brandon Lucke Wold
Journal:  Recent Trends Pharm Sci Res       Date:  2021

5.  Predictors of Opiate Utilization in the Treatment of Headache and Impact on Three-Month Outcomes Following Subarachnoid Hemorrhage.

Authors:  Dana Klavansky; Sheshali Wanchoo; Amanda Lin; Richard E Temes; Tania Rebeiz
Journal:  Cureus       Date:  2021-12-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.